The Life Sciences team advised GRIN Therapeutics, Inc. (“GRIN”) on an exclusive license agreement with Angelini Pharma S.p.A. (“Angelini”) to develop and commercialize radiprodil outside of North America. Under the terms of the agreement, GRIN Therapeutics will continue to lead global development and retain exclusive rights for radiprodil in the United States, Canada, and Mexico. Angelini Pharma will receive exclusive rights to commercialize radiprodil in the rest of the world. GRIN is to receive $50 million upfront and is eligible to receive up to $520 million in development, regulatory and sales milestones. In addition, GRIN is eligible to receive tiered royalties based on global sales as well as payments from any future sublicense transactions outside of Europe.
GRIN is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers. Late last year, GRIN reported promising topline data from a Phase 1b/2a clinical trial (the Honeycomb Trial, ClinicalTrials.gov NCT identifier: NCT05818943) evaluating radiprodil in GRIN-related neurodevelopmental disorder (GRIN-NDD) in patients with gain-of-function (GoF) variants, leading to the decision to advance to a global Phase 3 trial. The company has an additional ongoing clinical trial to evaluate radiprodil for the potential treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. GRIN Therapeutics is an affiliate of Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences.
The Goodwin team was led by Richard Hoffman, Noelle Dubiansky, Katerina Stavrianidis and Jo-an Chen; Catherine McCarty, Jessica Rothstein and Gina Kim; Curtis McCluskey and Federica De Santis; Susan Lee; Daniel Karelitz; Paul Jin, Eram Khan, Laurenz Bove and Brady Cummins; Jacob Osborn and Gozde Guckaya; Barry Bazian; with invaluable assistance from Sofia Wyman.
For more information, please read the press release.